Here's a link from drugs.com:
http://www.drugs.com/clinical_trials...nts-13353.html
It's supposed to work differently than other meds out there right now by keeping lymphocytes trapped, but they won't get their next phase of testing done until 2014 (I think it's phase III), so it'll be a while before we hear more talk about it. There's a link on the gov't clinical trials for it, but trials are by invite-only (fancy!):
http://clinicaltrials.gov/ct2/show/NCT01226745
Just wondering if anyone's herd anything from their neuros at all, or done any research and dug something up. Adverse events: "appeared to be generally dose related. Of note was a slower heartbeat and atrioventricular blocks associated with the initiation of treatment, which were asymptomatic, transient and did not require ONO-4641 discontinuation. Other notable adverse events included liver enzyme elevations. In addition, Grade 4 lymphopenia, which is an abnormally low level of lymphocytes in the blood, occurred in 4 percent of patients receiving the 0.15 mg dose of ONO-4641 and in 1 percent of those receiving the 0.10 mg dose".
I guess the neuros will be talking about it (and other stuff!) this week @ the American Academy of Neurology’s 64th Annual Meeting. Fingers crossed, all!
http://www.drugs.com/clinical_trials...nts-13353.html
It's supposed to work differently than other meds out there right now by keeping lymphocytes trapped, but they won't get their next phase of testing done until 2014 (I think it's phase III), so it'll be a while before we hear more talk about it. There's a link on the gov't clinical trials for it, but trials are by invite-only (fancy!):
http://clinicaltrials.gov/ct2/show/NCT01226745
Just wondering if anyone's herd anything from their neuros at all, or done any research and dug something up. Adverse events: "appeared to be generally dose related. Of note was a slower heartbeat and atrioventricular blocks associated with the initiation of treatment, which were asymptomatic, transient and did not require ONO-4641 discontinuation. Other notable adverse events included liver enzyme elevations. In addition, Grade 4 lymphopenia, which is an abnormally low level of lymphocytes in the blood, occurred in 4 percent of patients receiving the 0.15 mg dose of ONO-4641 and in 1 percent of those receiving the 0.10 mg dose".
I guess the neuros will be talking about it (and other stuff!) this week @ the American Academy of Neurology’s 64th Annual Meeting. Fingers crossed, all!
Comment